In This Article:
In a week marked by fluctuating indices and mixed economic signals, global markets have shown resilience amid busy earnings reports and complex labor market data. As investors navigate these turbulent waters, dividend stocks yielding up to 4.5% offer a potential avenue for steady income, appealing to those seeking stability in an uncertain economic environment.
Top 10 Dividend Stocks
| Name | Dividend Yield | Dividend Rating |
| Tsubakimoto Chain (TSE:6371) | 4.08% | ★★★★★★ |
| Mitsubishi Shokuhin (TSE:7451) | 3.87% | ★★★★★★ |
| Globeride (TSE:7990) | 4.04% | ★★★★★★ |
| Guangxi LiuYao Group (SHSE:603368) | 3.16% | ★★★★★★ |
| China South Publishing & Media Group (SHSE:601098) | 4.39% | ★★★★★★ |
| Innotech (TSE:9880) | 4.75% | ★★★★★★ |
| HUAYU Automotive Systems (SHSE:600741) | 4.63% | ★★★★★★ |
| Business Brain Showa-Ota (TSE:9658) | 4.11% | ★★★★★★ |
| Kwong Lung Enterprise (TPEX:8916) | 6.33% | ★★★★★★ |
| DoshishaLtd (TSE:7483) | 3.87% | ★★★★★★ |
Click here to see the full list of 1937 stocks from our Top Dividend Stocks screener.
Below we spotlight a couple of our favorites from our exclusive screener.
Sinopharm Group
Simply Wall St Dividend Rating: ★★★★★☆
Overview: Sinopharm Group Co. Ltd., along with its subsidiaries, operates in the wholesale and retail sectors of pharmaceuticals, medical devices, and healthcare products in the People’s Republic of China, with a market capitalization of approximately HK$63.66 billion.
Operations: Sinopharm Group Co. Ltd.'s revenue is derived from its activities in the wholesale and retail distribution of pharmaceuticals, medical devices, and healthcare products across China.
Dividend Yield: 4.6%
Sinopharm Group offers a reliable dividend yield of 4.59%, though it falls short compared to the top 25% of dividend payers in Hong Kong. The company's dividends are well-covered by both earnings and cash flows, with payout ratios of 33% and 39.5%, respectively, indicating sustainability. Despite recent executive changes and a slight decline in net income to CNY 5.28 billion for the first nine months of 2024, dividends remain stable and have shown growth over the past decade.
-
Delve into the full analysis dividend report here for a deeper understanding of Sinopharm Group.
-
Our valuation report here indicates Sinopharm Group may be undervalued.
Henan Lingrui Pharmaceutical
Simply Wall St Dividend Rating: ★★★★★☆
Overview: Henan Lingrui Pharmaceutical Co., Ltd. is a company that produces and sells medicines in China, with a market cap of CN¥12.73 billion.
Operations: Henan Lingrui Pharmaceutical Co., Ltd. generates its revenue from the production and sale of medicines within China.
Dividend Yield: 3.5%
Henan Lingrui Pharmaceutical's dividend yield of 3.54% ranks in the top 25% of CN market payers, supported by earnings and cash flows with payout ratios of 66.3% and 73.7%. Despite a volatile dividend history, recent earnings growth—net income rose to CNY 573.87 million for nine months ending September 2024—suggests potential stability. The stock trades at good value relative to peers, though its dividend reliability remains uncertain due to past volatility.